Tissue ACE Inhibitors for Secondary Prevention of Cardiovascular Disease in Patients With Preserved Left Ventricular Function: A Pooled Meta-analysis of Randomized Placebo-controlled Trials
Free accessResearch articleFirst published online September, 2007
Tissue ACE Inhibitors for Secondary Prevention of Cardiovascular Disease in Patients With Preserved Left Ventricular Function: A Pooled Meta-analysis of Randomized Placebo-controlled Trials
Objective. A pooled meta-analysis of published, randomized placebo-controlled clinical trials to evaluate the role of tissue angiotensin-converting enzyme (ACE) inhibitors in secondary prevention of cardiovascular disease in patients with preserved left ventricular function. Sources. Peer-reviewed journals listed in Index Medicus/MEDLINE, the Cochrane Central Register of Controlled Clinical Trials, and the Cochrane Database of Systematic Reviews. Study selection . Randomized placebo-controlled clinical trials of at least 12 months' duration, in patients with a prior cardiovascular event or at high risk for cardiovascular events, were analyzed. Data synthesis and analysis. A total of 31 555 patients (136 882 patient-years) from 4 trials were selected for the meta-analysis. Relative risk estimations were made using data pooled from these trials, and statistical significance was determined using the χ2 test. The number of patients needed to treat was also calculated for each outcome. Results. Tissue ACE inhibitors significantly reduced the risk of all-cause mortality, cardiovascular mortality, acute myocardial infarction, and stroke (P < .001 for each). The need for invasive coronary revascularization was reduced (P = .03), as was the risk of hospitalization for congestive heart failure (P = .001). The occurrence of new-onset diabetes was also significantly reduced (P < .001), but the risk of hospitalization for angina was not significantly affected (P = .677). Treating about 100 patients for about 4.5 years would prevent 1 death, 1 non-fatal myocardial infarction, 1 cardiovascular death, or 1 invasive coronary revascularization. Conclusions. Tissue ACE inhibitors have demonstrated benefit when used for secondary prevention of cardiovascular disease in patients with preserved left ventricular function in randomized placebo-controlled clinical trials.
Jackson EKRenin and angiotensin. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics . 10th ed. New York, NY: McGraw-Hill; 2001:809-829.
2.
Brown NJ, Vaughan DEAngiotensin-converting enzyme inhibitors. Circulation. 1998;97:1411-1420.
3.
Sokol SI, Portnay EL, Curtis JP, et al. Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke. Neurology. 2004;63:208-213.
4.
Sica DAClass effects of angiotensin-converting enzyme inhibitors. Am J Manag Care.2000;6(suppl):S85-S108.
5.
Campbell DJCirculating and tissue angiotensin systems. J Clin Invest.1987;79:1-6.
6.
Vane JRAngiotensin. In: Page H, Bumpus FM, eds. Handbook of Experimental Pharmacology . New York, NY: Springer-Verlag ; 1974:17-39.
7.
Ng KK, Vane JRFate of angiotensin I in the circulation. Nature. 1968;218:144-150.
8.
Dzau VJ, Re RNEvidence for the existence of renin in the heart. Circulation . 1987;75(suppl I):1134-1136.
9.
Sun Y., Zhang J., Zhang JQ, et al. Renin expression at sites of repair in the infracted rat heart . J Mol Cell Cardiol. 2001;33:995-1003.
10.
Okamura A., Rakugi H., Ohishi M., et al. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J Hypertens.1999;17:537-545.
11.
Swales JDArterial wall or plasma renin in hypertension. Clin Sci.1979;56:293-298.
12.
Ganten D., Hermann K., Bayer C., et al. Angiotensin synthesis in the brain and increased turnover in hypertensive rats. Science. 1983;221:869-871.
13.
Inagami T.Renin in the brain and neuroblastoma cells: an endogenous and intracellular system. Neuroendocrinology. 1982;35:475-482.
14.
Johren O., Imboden H., Hauser W., et al. Localization of angiotensin-converting enzyme, angiotensin II, angiotensin II receptor subtypes, and vasopressin in the mouse hypothalamus . Brain Res.1997;757:218-227.
15.
Celio MR, Inagami T.Angiotensin II immunoreactivity coexists with renin in the juxtaglomerular granular cells of the kidney. Proc Natl Acad Sci USA. 1981;78:3897-3900.
16.
Taugner R., Hackenthal E., Helmchen U., et al. The intrarenal renin-angiotensin-system. An immunocytochemical study on the localization of renin, angiotensinogen, converting enzyme and the angiotensins in the kidney of mouse and rat. Klin Wochenschr.1982;60:1218-1222.
17.
Ganten D., Hermann K., Unger T., et al. The tissue reninangiotensin systems: focus on brain angiotensin, adrenal gland and arterial wall. Clin Exp Hypertens A. 1983; 5:1099-1118.
18.
Pandey KN, Misono KS, Inagami T.Evidence for intracellular formation of angiotensins: coexistence of renin and angiotensin-converting enzyme in Leydig cells of rat testis. Biochem Biophys Res Commun.1984;122:1337-1343.
19.
Schling P., Mallow H., Trindl A., Loffler G.Evidence for a local renin angiotensin system in primary cultured human preadipocytes . Int J Obes Relat Metab Disord.1999;23:336-341.
20.
Oliver JA, Sciacca RRLocal generation of angiotensin II as a mechanism of regulation of peripheral vascular tone in the rat. J Clin Invest.1984 ;74:1247-1251.
21.
Nakamaru M. , Jackson EK, Inagami T.Beta-adrenoceptormediated release of angiotensin II from mesenteric arteries. Am J Physiol.1986;250:H144-H148.
22.
Ruzicka M., Skarda V., Leenen FHEffects of ACE inhibitors on circulating versus cardiac angiotensin II in volume overload—induced cardiac hypertrophy in rats. Circulation. 1995;92:3568-3573.
23.
Pieruzzi F. , Abassi ZA, Keiser HRExpression of reninangiotensin system components in the heart, kidneys and lungs of rats with experimental heart failure. Circulation. 1995;92:3105-3112.
24.
Hirsch AT, Talsness CE, Schunkert H., et al. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res.1991;69:475-482.
25.
Fabris B., Jackson B., Kohzuki M., et al. Increased cardiac angiotensin-converting enzyme in rats with chronic heart failure. Clin Exp Pharmacol Physiol. 1990;17: 309-314.
26.
Hokimoto S. , Yasue H., Fujimoto K., et al. Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction . Circulation. 1996;94:1513-1518.
27.
Re RNTissue renin angiotensin systems. Med Clin North Am.2004;88:19-38.
28.
Dzau VJ, Bernstein K., Celermajer D., et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol.2001;88(suppl):1L-20L.
29.
Waeber B., Gavras I., Brunner HR, et al. Prediction of sustained antihypertensive efficacy of chronic captopril therapy: relationships to immediate blood pressure response and control plasma renin activity. Am Heart J.1982;103: 384-390.
30.
Lund-Johansen P., Omvik P.Long-term haemodynamic effects of enalapril (alone and in combination with hydrochlorothiazide) at rest and during exercise in essential hypertension. J Hypertens.1984 ;2:S49-S50.
31.
Dunn GF, Oigman W., Ventura HO, et al. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol.1984;53:105-108.
32.
Fouad FM, Tarazi RC, Bravo ELCardiac and haemodynamic effects of enalapril. J Hypertens.1983;1(suppl 1):135-142.
33.
Atlas SA, Case DB, Sealey JE, et al. Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertension. 1979; 1:274-280.
34.
Patten RD, Udelson JE, Konstam MAVentricular remodeling and its prevention in the treatment of heart failure . Curr Opin Cardiol. 1998;13:162-167.
35.
The SOLVD Investigators.Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med.1992;327:685-691.
36.
Pfeffer MA, Braunwald E., Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med.1992;327:669-677.
37.
Braunwald E., Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non—ST-segment elevation myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). http://www.acc.org/qualityandscience/clinical/guidelines/unstable/incorporated/UA_incorporated.pdf. Accessed March 15, 2007.
38.
Antman EM, Anbe DT, Armstrong PW, et al. ACC/ AHA guidelines for the management of patients with ST-Elevation myocardial infarction—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004;44:671-719.
39.
The Task Force on ACE-Inhibitors of the European Society of Cardiology.Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. Eur Heart J.2004;25:1454-1470.
40.
Cohn JN, Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med.1991;325:303-310.
41.
The CONSENSUS Trial Study Group.Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) . N Engl J Med.1987; 316:1429-1435.
42.
GruppoItaliano per lo Studio della Sopravvivenza nell'infarcto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction . Lancet. 1994;343:1115-1122.
43.
ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group.ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected myocardial infarction. Lancet. 1995;345:669-685.
44.
AceInhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction—systematic overview of individual data from 100 000 patients in randomized trials. Circulation . 1998;97:2202-2212.
45.
Flather MD, Yusuf S., Kober L., et al; ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet . 2000;355:1575-1581.
46.
The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
47.
Torp-Pederson C., Kober L.; TRACE Study Group. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. Lancet. 1999;354:9-12.
48.
The Heart Outcomes Prevention Evaluation Study Investigators.Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med.2000;342:145-153.
49.
The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators.Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial. Lancet. 2003;362:782-788.
50.
The PEACE Trial Investigators.Angiotensin-converting-enzyme inhibition in stable coronary artery disease . N Engl J Med.2004;351:2058-2068.
51.
Pitt B., O'Neill B., Feldman R., et al. The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol.2001 ;87:1058-1063.
52.
PROGRESS Collaborative Group.Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
53.
Marre M., Lievre M., Chatellier G., et al. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomized, double-blind, placebo controlled trial (the DIA-BHYCAR study) [published online ahead of print February 28, 2004]. BMJ. doi:10.1136/bmj.37970.629537.0D.
54.
Moher D., Cook DJ, Eastwood S., et al. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Lancet.1999; 354:1896-1900.
55.
Verhagen AP , de Vet Hcw, de Bie RA, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol.1998;51: 1235-1241.
56.
Lam RW, Kennedy SHUsing meta-analysis to evaluate evidence: practical tips and traps. Can J Psychiatry.2005; 50:167-174.
The ALLHAT Collaborative Research Group.Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA.2002;288:2981-2997.
59.
Wing LM, Reid CM, Ryan P., et al; High Blood Pressure Research Council of Australia. Second Australian National Blood Pressure Study (ANBP2). Australian Comparative Outcome Trial of ACE inhibitor- and diuretic-based treatment of hypertension in the elderly . Clin Exp Hypertens. 1997;19:779-791.
60.
Abuissa H., Jones PG, Marso SP, et al. Angiotensinconverting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol.2005; 46:821-826.
61.
MacMahon S. , Sharpe N., Gamble G., et al; PART-2 Collaborative Research Group.Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J Am Coll Cardiol.2000;36: 438-443.
62.
Kjøller-Hansen L., Steffensen R., Grande P.The Angiotensinconverting Enzyme Inhibition Post Revascularization Study (APRES). J Am Coll Cardiol. 2000;35:881-888.
63.
Otsuka M., Yamamoto H., Okimoto T., et al. Long-term effects of quinapril with high affinity for tissue angiotensin-converting enzyme after coronary intervention in Japanese. Am Heart J.2004;147:662-668.
64.
Borghi C., Marino P., Zardini P., et al. Short- and longterm effects of early fosinopril administration in patients with acute anterior myocardial infarction undergoing intravenous thrombolysis: results from the Fosinopril in Acute Myocardial Infarction Study . Am Heart J.1998;136:213-225.
65.
Carter AO, Griffin GH, Carter TPA survey identified publication bias in the secondary literature. J Clin Epidemiol.2006;59:241-245.
